vTv Therapeutics Inc.
VTVTHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframevTv Therapeutics Inc. vTv Therapeutics Inc., a late-stage biopharmaceutical company, focuses on developing oral small molecule drug candidates intended to treat people living with diabetes and other chronic diseases. Valued at $101.0M, VTVT is a micro-cap name in its sector. Its lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial to treat type 1 diabetes.
Market Cap
$101.0M
Beta
0.21
P/E (TTM)
—
P/E (Fwd)
-5.83
EPS (TTM)
$-0.72
EPS (Fwd)
$-4.38
ROE
-15.8%
ROA
-10.1%
Cash
$86.6M
Total Debt
$0
Free CF
$674,375
52W Change
22.3%
Annual Financials
Cash vs Debt
Where VTVT stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, VTVT finished 17.76% below its 150-day moving average ($33.55) and 19.37% below its 200-day moving average ($34.22). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is VTVT overbought or oversold?
At the October 16, 2026 close, VTVT's RSI(14) was 38.4, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
vTv Therapeutics Inc. reports $86.6M in cash and $0 in total debt. Annual free cash flow of $674K supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of -15.8% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $4.0M (2021) to $0 (2025), a 100% decline worth watching.
With a beta below 0.7, vTv Therapeutics Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing VTVT's risk profile alongside its fundamentals and technical indicators provides a more complete picture.